NGM Biopharmaceuticals names William Rieflin CEO
This article was originally published in Scrip
NGM Biopharmaceuticals (US), a privately-held biotech firm focused on the discovery and development of biotherapeutics for the treatment of type 2 diabetes and other metabolic diseases, has named William Rieflin chief executive officer and a member of its board of directors. Mr Rieflin, who has more than 20 years' industry experience, was most recently president of XenoPort. Before that, he was executive vice-president of administration, chief financial officer, general counsel and secretary at Tularik, which was acquired by Amgen in 2004.